Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 7 | 2022 | 2519 | 1.200 |
Why?
|
| Biological Therapy | 1 | 2022 | 138 | 0.770 |
Why?
|
| Propensity Score | 3 | 2023 | 1781 | 0.760 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2023 | 816 | 0.710 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2022 | 2425 | 0.670 |
Why?
|
| Veterans Health | 1 | 2019 | 216 | 0.620 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 867 | 0.540 |
Why?
|
| Models, Statistical | 2 | 2020 | 5102 | 0.510 |
Why?
|
| Biological Products | 1 | 2022 | 860 | 0.430 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5221 | 0.420 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 1912 | 0.310 |
Why?
|
| Public Housing | 2 | 2023 | 145 | 0.250 |
Why?
|
| Electronic Health Records | 1 | 2020 | 4468 | 0.230 |
Why?
|
| Smoking | 1 | 2019 | 8987 | 0.220 |
Why?
|
| Housing | 2 | 2023 | 664 | 0.200 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 13102 | 0.190 |
Why?
|
| Medicare Part D | 1 | 2024 | 328 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 221 | 0.160 |
Why?
|
| Amlodipine | 1 | 2018 | 83 | 0.160 |
Why?
|
| Hydrochlorothiazide | 1 | 2018 | 98 | 0.160 |
Why?
|
| Massachusetts | 4 | 2023 | 8663 | 0.160 |
Why?
|
| Metoprolol | 1 | 2018 | 93 | 0.160 |
Why?
|
| Gastrointestinal Agents | 1 | 2022 | 494 | 0.150 |
Why?
|
| United States | 12 | 2024 | 69872 | 0.150 |
Why?
|
| Aged | 14 | 2024 | 163280 | 0.150 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2021 | 875 | 0.140 |
Why?
|
| Prescription Drugs | 1 | 2024 | 595 | 0.140 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 612 | 0.140 |
Why?
|
| Computer Simulation | 2 | 2020 | 6196 | 0.140 |
Why?
|
| Sample Size | 1 | 2019 | 845 | 0.140 |
Why?
|
| Humans | 32 | 2024 | 744343 | 0.130 |
Why?
|
| Prenatal Diagnosis | 1 | 2022 | 1236 | 0.130 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 3086 | 0.130 |
Why?
|
| Fees, Pharmaceutical | 1 | 2015 | 64 | 0.130 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2022 | 941 | 0.120 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2019 | 518 | 0.120 |
Why?
|
| Medicare | 2 | 2022 | 6566 | 0.120 |
Why?
|
| Group Homes | 2 | 2023 | 34 | 0.120 |
Why?
|
| Piperidines | 1 | 2022 | 1602 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2022 | 4420 | 0.110 |
Why?
|
| Melanoma | 2 | 2022 | 5510 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2022 | 1591 | 0.100 |
Why?
|
| Scopolamine Derivatives | 1 | 2011 | 23 | 0.100 |
Why?
|
| ROC Curve | 1 | 2019 | 3527 | 0.100 |
Why?
|
| Methylphenidate | 1 | 2015 | 473 | 0.100 |
Why?
|
| Comorbidity | 2 | 2022 | 10388 | 0.100 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 11727 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2022 | 2071 | 0.090 |
Why?
|
| Prognosis | 2 | 2022 | 29063 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 1587 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2022 | 2942 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 1671 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 2020 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 2046 | 0.080 |
Why?
|
| Bronchodilator Agents | 1 | 2011 | 502 | 0.080 |
Why?
|
| Mortality | 1 | 2019 | 2864 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2024 | 40561 | 0.080 |
Why?
|
| Thrombosis | 1 | 2022 | 2968 | 0.080 |
Why?
|
| Aminopyridines | 1 | 2011 | 542 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2019 | 2265 | 0.080 |
Why?
|
| Risk Factors | 7 | 2024 | 72290 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2015 | 1148 | 0.070 |
Why?
|
| Benzamides | 1 | 2011 | 1379 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 9959 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 1956 | 0.060 |
Why?
|
| Atrial Fibrillation | 1 | 2024 | 5034 | 0.060 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 3079 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2023 | 6600 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 2219 | 0.060 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 5181 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2015 | 2063 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 19905 | 0.060 |
Why?
|
| Patient Selection | 1 | 2015 | 4215 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 5751 | 0.050 |
Why?
|
| Middle Aged | 7 | 2022 | 213383 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 2872 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2022 | 63114 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2022 | 77449 | 0.050 |
Why?
|
| Male | 9 | 2024 | 350118 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 5686 | 0.050 |
Why?
|
| Blood Sedimentation | 1 | 2022 | 231 | 0.050 |
Why?
|
| Stroke | 1 | 2024 | 9981 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 57776 | 0.050 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 25043 | 0.050 |
Why?
|
| Female | 12 | 2024 | 380194 | 0.050 |
Why?
|
| Sweden | 1 | 2024 | 1345 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 39050 | 0.050 |
Why?
|
| Insulin | 1 | 2015 | 6580 | 0.050 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2015 | 3658 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2022 | 426 | 0.040 |
Why?
|
| Obesity | 1 | 2022 | 12745 | 0.040 |
Why?
|
| Adult | 7 | 2023 | 214055 | 0.040 |
Why?
|
| Ferritins | 1 | 2022 | 590 | 0.040 |
Why?
|
| Vaginal Smears | 1 | 2021 | 511 | 0.040 |
Why?
|
| Pandemics | 3 | 2023 | 8388 | 0.040 |
Why?
|
| Hypertension | 1 | 2018 | 8480 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2024 | 855 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2022 | 1588 | 0.040 |
Why?
|
| SEER Program | 1 | 2022 | 1508 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2022 | 1179 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 3047 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 15165 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 857 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2023 | 1036 | 0.030 |
Why?
|
| Minority Groups | 1 | 2024 | 1223 | 0.030 |
Why?
|
| HIV Infections | 1 | 2022 | 16718 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 20822 | 0.030 |
Why?
|
| Registries | 2 | 2022 | 8089 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2021 | 1119 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2022 | 1379 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 1915 | 0.030 |
Why?
|
| Random Allocation | 1 | 2018 | 2429 | 0.030 |
Why?
|
| Aging | 2 | 2022 | 8664 | 0.030 |
Why?
|
| Women's Health | 1 | 2022 | 2034 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 3616 | 0.030 |
Why?
|
| Social Class | 1 | 2021 | 1999 | 0.030 |
Why?
|
| Mammography | 1 | 2023 | 2476 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 1 | 2024 | 2647 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2022 | 3200 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2024 | 2838 | 0.030 |
Why?
|
| Neoplasms | 1 | 2020 | 21683 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 841 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 11725 | 0.020 |
Why?
|
| Boston | 1 | 2023 | 9313 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2011 | 416 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2015 | 681 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2022 | 2987 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 3778 | 0.020 |
Why?
|
| Child Behavior | 1 | 2015 | 839 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2015 | 2618 | 0.020 |
Why?
|
| Markov Chains | 1 | 2011 | 969 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2022 | 5317 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 7913 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 3913 | 0.020 |
Why?
|
| Recurrence | 1 | 2019 | 8340 | 0.020 |
Why?
|
| Adolescent Behavior | 1 | 2015 | 1151 | 0.020 |
Why?
|
| Health Services | 1 | 2011 | 758 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2011 | 1959 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 4149 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2024 | 21746 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3158 | 0.020 |
Why?
|
| Mass Screening | 1 | 2021 | 5255 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 15540 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 5078 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2011 | 1683 | 0.020 |
Why?
|
| Time Factors | 2 | 2021 | 40075 | 0.020 |
Why?
|
| Incidence | 1 | 2022 | 20947 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 5319 | 0.010 |
Why?
|
| Hospitalization | 1 | 2022 | 10262 | 0.010 |
Why?
|
| Child | 2 | 2022 | 77709 | 0.010 |
Why?
|
| Pregnancy | 1 | 2022 | 29144 | 0.010 |
Why?
|
| Infant | 1 | 2022 | 35136 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 15076 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 5391 | 0.010 |
Why?
|
| Health Status | 1 | 2011 | 4034 | 0.010 |
Why?
|
| Brain | 1 | 2024 | 26385 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 35421 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2015 | 23338 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 85781 | 0.000 |
Why?
|
Concepts
(159)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(52)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_